On the public citation graph
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
0 signed · 655 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2012.20openalex-snapshot
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
inferredcites →https://doi.org/10.1001/jama.283.17.2260openalex-snapshot
Clinicopathologic Features of BRCA -Linked and Sporadic Ovarian Cancer
inferredcites →https://doi.org/10.1001/jamaoncol.2015.2151openalex-snapshot
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
inferredcites →https://doi.org/10.1016/j.cell.2014.12.033openalex-snapshot
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
inferredcites →https://doi.org/10.1016/j.dnarep.2012.10.004openalex-snapshot
DNA polymerase POLQ and cellular defense against DNA damage
inferredcites →https://doi.org/10.1038/modpathol.2008.191openalex-snapshot
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
inferredcites →https://doi.org/10.1038/modpathol.2011.183openalex-snapshot
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
inferredcites →https://doi.org/10.1038/modpathol.2014.143openalex-snapshot
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
inferredcites →https://doi.org/10.1038/nature12477openalex-snapshot
Signatures of mutational processes in human cancer
inferredcites →https://doi.org/10.1038/nature12912openalex-snapshot
Discovery and saturation analysis of cancer genes across 21 tumour types
inferredcites →https://doi.org/10.1038/nature14011openalex-snapshot
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
inferredcites →https://doi.org/10.1038/nature14157openalex-snapshot
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
inferredcites →https://doi.org/10.1038/nature14184openalex-snapshot
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
inferredcites →https://doi.org/10.1038/nature14410openalex-snapshot
Whole–genome characterization of chemoresistant ovarian cancer
inferredcites →https://doi.org/10.1038/nbt.3344openalex-snapshot
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
inferredcites →https://doi.org/10.1056/nejmoa020177openalex-snapshot
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1200694openalex-snapshot
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1056/nejmoa1500596openalex-snapshot
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
inferredcites →https://doi.org/10.1073/pnas.0509182102openalex-snapshot
Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
inferredcites →https://doi.org/10.1073/pnas.0611533104openalex-snapshot
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
inferredcites →https://doi.org/10.1097/pas.0b013e31826cabbdopenalex-snapshot
BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
inferredcites →https://doi.org/10.1101/gr.165985.113openalex-snapshot
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0066openalex-snapshot
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
inferredcites →https://doi.org/10.1158/2159-8290.cd-11-0184openalex-snapshot
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0863openalex-snapshot
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-1397openalex-snapshot
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-0714openalex-snapshot
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1182/blood-2014-04-567933openalex-snapshot
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
inferredcites →https://doi.org/10.1371/journal.pone.0000796openalex-snapshot
NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
inferredcites →https://doi.org/10.1371/journal.pone.0080023openalex-snapshot
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
inferredcites →https://doi.org/10.17615/hvp3-wg08openalex-snapshot
Integrated genomic analyses of ovarian carcinoma
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4820044openalex-extracted
The Mutational Landscape of Homologous Recombination Repair (Hrr) Genes and Their Impacts on Metastatic Colorectal Cancer Patients Treated With Immunotherapy
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.25109openalex-snapshot
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
inferred← citeshttps://doi.org/10.1001/jamaoncol.2017.3290openalex-snapshot
Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.1029openalex-snapshot
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.3343openalex-snapshot
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
inferred← citeshttps://doi.org/10.1002/adbi.202400720openalex-snapshot
Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)
inferred← citeshttps://doi.org/10.1002/cam4.2849openalex-snapshot
Association between DNA damage repair gene somatic mutations and immune‐related gene expression in ovarian cancer
inferred← citeshttps://doi.org/10.1002/cam4.3831openalex-snapshot
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1002/cam4.71065openalex-snapshot
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/cncr.31307openalex-snapshot
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
inferred← citeshttps://doi.org/10.1002/ctm2.70836openalex-snapshot
Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer
inferred← citeshttps://doi.org/10.1002/gcc.22935openalex-snapshot
PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials
inferred← citeshttps://doi.org/10.1002/hep.30482openalex-snapshot
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
inferred← citeshttps://doi.org/10.1002/ijc.32358openalex-snapshot
Variant classification in precision oncology
inferred← citeshttps://doi.org/10.1002/ijc.33038openalex-snapshot
Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment
inferred← citeshttps://doi.org/10.1002/ijc.33918openalex-snapshot
PARP mediated DNA damage response, genomic stability and immune responses
inferred← citeshttps://doi.org/10.1002/jha2.549openalex-snapshot
Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
inferred← citeshttps://doi.org/10.1002/kjm2.12375openalex-snapshot
Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
inferred← citeshttps://doi.org/10.1002/mdr2.70032openalex-snapshot
Rad51 at the Crossroads: Bridging DNA Repair, Tumorigenesis, and Immune Regulation
inferred← citeshttps://doi.org/10.1007/13905_2024_40openalex-snapshot
The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1007/13905_2025_49openalex-snapshot
Immunotherapy in Early Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4939-9500-4_1openalex-snapshot
Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers
inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_51openalex-snapshot
Ovarian Cancer, Early Primary Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-57949-4_20openalex-snapshot
Immunology and Immunotherapy of Ovarian Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-73359-9_3openalex-snapshot
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_289-1openalex-snapshot
The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?
inferred← citeshttps://doi.org/10.1007/978-3-031-30065-3_7openalex-snapshot
Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-38623-7_6openalex-snapshot
Immunotherapy in Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-00773-5_289openalex-snapshot
The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?
inferred← citeshttps://doi.org/10.1007/978-981-16-1873-4_2openalex-snapshot
An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology
inferred← citeshttps://doi.org/10.1007/978-981-16-1873-4_3openalex-snapshot
The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
inferred← citeshttps://doi.org/10.1007/978-981-99-7141-1_5openalex-snapshot
PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer
inferred← citeshttps://doi.org/10.1007/s00018-019-03299-8openalex-snapshot
Targeting DNA repair in cancer: current state and novel approaches
inferred← citeshttps://doi.org/10.1007/s00066-019-01571-1openalex-snapshot
Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy
inferred← citeshttps://doi.org/10.1007/s00129-022-04963-0openalex-snapshot
Ovarialkarzinom: Immuntherapie, quo vadis?
inferred← citeshttps://doi.org/10.1007/s00262-019-02393-xopenalex-snapshot
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00262-021-03050-yopenalex-snapshot
Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer
inferred← citeshttps://doi.org/10.1007/s00281-022-00979-9openalex-snapshot
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors
inferred← citeshttps://doi.org/10.1007/s00428-020-02751-6openalex-snapshot
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
inferred← citeshttps://doi.org/10.1007/s00432-021-03778-1openalex-snapshot
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status
inferred← citeshttps://doi.org/10.1007/s00761-018-0511-zopenalex-snapshot
Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation
inferred← citeshttps://doi.org/10.1007/s10120-025-01648-0openalex-snapshot
Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer
inferred← citeshttps://doi.org/10.1007/s10269-016-2664-yopenalex-snapshot
Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1)
inferred← citeshttps://doi.org/10.1007/s10456-020-09734-wopenalex-snapshot
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
inferred← citeshttps://doi.org/10.1007/s10549-022-06786-yopenalex-snapshot
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers
inferred← citeshttps://doi.org/10.1007/s10585-024-10307-0openalex-snapshot
Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis
inferred← citeshttps://doi.org/10.1007/s10689-019-00129-5openalex-snapshot
Genetic counseling referral for ovarian cancer patients: a call to action
inferred← citeshttps://doi.org/10.1007/s11356-021-16726-wopenalex-snapshot
Unboxing the molecular modalities of mutagens in cancer
inferred← citeshttps://doi.org/10.1007/s11864-018-0584-3openalex-snapshot
Review of Immune Therapies Targeting Ovarian Cancer
inferred← citeshttps://doi.org/10.1007/s11864-018-0593-2openalex-snapshot
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
inferred← citeshttps://doi.org/10.1007/s11864-019-0634-5openalex-snapshot
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
inferred← citeshttps://doi.org/10.1007/s11864-023-01087-yopenalex-snapshot
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
inferred← citeshttps://doi.org/10.1007/s11912-016-0515-zopenalex-snapshot
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
inferred← citeshttps://doi.org/10.1007/s11912-020-00933-8openalex-snapshot
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
inferred← citeshttps://doi.org/10.1007/s11912-021-01088-wopenalex-snapshot
Frontline Maintenance Treatment for Ovarian Cancer
inferred← citeshttps://doi.org/10.1007/s12013-023-01192-7openalex-snapshot
Immune Features of Tumor Microenvironment: A Genetic Spotlight
inferred← citeshttps://doi.org/10.1007/s12032-021-01507-9openalex-snapshot
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer
inferred← citeshttps://doi.org/10.1007/s12253-019-00735-9openalex-snapshot
Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
inferred← citeshttps://doi.org/10.1007/s12282-026-01878-9openalex-snapshot
BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study
inferred← citeshttps://doi.org/10.1007/s12325-019-01051-zopenalex-snapshot
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
inferred← citeshttps://doi.org/10.1007/s12672-026-04785-9openalex-snapshot
Current evidence and emerging approaches in immunotherapy for gynecological cancers
inferred← citeshttps://doi.org/10.1007/s12672-026-05030-zopenalex-snapshot
The mechanisms and clinical prospects of combining chemotherapy with immunotherapy for advanced pancreatic cancer
inferred← citeshttps://doi.org/10.1007/s40259-020-00450-xopenalex-snapshot
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
inferred← citeshttps://doi.org/10.1007/s40265-020-01270-7openalex-snapshot
Mechanisms of Resistance to PD-1 Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/s40487-021-00167-zopenalex-snapshot
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
inferred← citeshttps://doi.org/10.1016/b978-0-12-813753-6.00011-1openalex-snapshot
PARP Inhibition to Enhance Response to Chemotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00080-3openalex-snapshot
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
inferred← citeshttps://doi.org/10.1016/b978-0-323-77684-4.00014-3openalex-snapshot
Adenocarcinoma of the uterine corpus and sarcomas of the uterus
inferred← citeshttps://doi.org/10.1016/b978-0-323-77684-4.00026-xopenalex-snapshot
Immunotherapy in gynecologic malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-323-87763-3.00014-9openalex-snapshot
Tumor antigenicity and cancer as non-self
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2018.11.004openalex-snapshot
Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling
inferred← citeshttps://doi.org/10.1016/j.adro.2018.08.017openalex-snapshot
The DNA damage response in immunotherapy and radiation
inferred← citeshttps://doi.org/10.1016/j.annpat.2020.02.015openalex-snapshot
Les tumeurs héréditaires de l’ovaire vues par le pathologiste
inferred← citeshttps://doi.org/10.1016/j.apsb.2021.01.003openalex-snapshot
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bbcan.2021.188661openalex-snapshot
Genomic instability, inflammatory signaling and response to cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.189017openalex-snapshot
Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.114359openalex-snapshot
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells
inferred← citeshttps://doi.org/10.1016/j.biopha.2018.01.094openalex-snapshot
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110204openalex-snapshot
Therapeutic applications of PARP inhibitors in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.biopha.2026.119670openalex-snapshot
Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
inferred← citeshttps://doi.org/10.1016/j.bulcan.2017.09.007openalex-snapshot
Anomalies de la réparation de l’ADN et cancers gynécologiques
inferred← citeshttps://doi.org/10.1016/j.bulcan.2019.11.015openalex-snapshot
Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.02.027openalex-snapshot
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2025.218183openalex-snapshot
Overcoming radioresistance in prostate cancer by targeting DNA damage repair
inferred← citeshttps://doi.org/10.1016/j.cell.2024.02.041openalex-snapshot
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
inferred← citeshttps://doi.org/10.1016/j.cellimm.2018.01.013openalex-snapshot
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109412openalex-snapshot
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
inferred← citeshttps://doi.org/10.1016/j.clgc.2018.11.021openalex-snapshot
Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.06.013openalex-snapshot
Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation
inferred← citeshttps://doi.org/10.1016/j.clinthera.2018.01.005openalex-snapshot
An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
inferred← citeshttps://doi.org/10.1016/j.cll.2023.08.004openalex-snapshot
Molecular Pathology of Ovarian Epithelial Neoplasms
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.07.014openalex-snapshot
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
inferred← citeshttps://doi.org/10.1016/j.clon.2018.05.008openalex-snapshot
Personalising Treatment for High-Grade Serous Ovarian Carcinoma
inferred← citeshttps://doi.org/10.1016/j.coi.2016.07.005openalex-snapshot
Neoantigens encoded in the cancer genome
inferred← citeshttps://doi.org/10.1016/j.coisb.2017.04.005openalex-snapshot
Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2023.106836openalex-snapshot
Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response
inferred← citeshttps://doi.org/10.1016/j.cpt.2025.08.005openalex-snapshot
Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2017.04.006openalex-snapshot
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104469openalex-snapshot
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2017.07.008openalex-snapshot
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
inferred← citeshttps://doi.org/10.1016/j.ctrv.2018.12.002openalex-snapshot
PARP inhibitors in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2026.103094openalex-snapshot
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials
inferred← citeshttps://doi.org/10.1016/j.dnarep.2019.06.005openalex-snapshot
DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.dnarep.2021.103112openalex-snapshot
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.dnarep.2022.103409openalex-snapshot
The DNA damage induced immune response: Implications for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.dnarep.2023.103594openalex-snapshot
DNA repair deficiency and the immune microenvironment: A pathways perspective
inferred← citeshttps://doi.org/10.1016/j.drup.2021.100744openalex-snapshot
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.08.029openalex-snapshot
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ejcsup.2019.12.002openalex-snapshot
Inflammation and immunity in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ejphar.2022.174957openalex-snapshot
DNA damage response and repair in the development and treatment of brain tumors
inferred← citeshttps://doi.org/10.1016/j.gore.2018.06.011openalex-snapshot
Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
inferred← citeshttps://doi.org/10.1016/j.gpb.2023.02.004openalex-snapshot
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e38888openalex-snapshot
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.heliyon.2026.e44610openalex-snapshot
Inhibition of replication origins and ATR synergistically activates the innate immune system in cancer cells
inferred← citeshttps://doi.org/10.1016/j.hoc.2018.07.006openalex-snapshot
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2024.125028openalex-snapshot
Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108340openalex-snapshot
Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109236openalex-snapshot
Research progress of neoantigens in gynecologic cancers
inferred← citeshttps://doi.org/10.1016/j.isci.2025.112860openalex-snapshot
Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification
inferred← citeshttps://doi.org/10.1016/j.isci.2026.116587openalex-snapshot
Reversal of T cell exhaustion enables cancer vaccine efficacy in BRCA1-deficient ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.05.014openalex-snapshot
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
inferred← citeshttps://doi.org/10.1016/j.lfs.2020.118434openalex-snapshot
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
inferred← citeshttps://doi.org/10.1016/j.lfs.2022.120827openalex-snapshot
Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.09.016openalex-snapshot
WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.11.013openalex-snapshot
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.06.025openalex-snapshot
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
inferred← citeshttps://doi.org/10.1016/j.medj.2024.07.022openalex-snapshot
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
inferred← citeshttps://doi.org/10.1016/j.molcel.2016.05.021openalex-snapshot
When Genome Maintenance Goes Badly Awry
inferred← citeshttps://doi.org/10.1016/j.molcel.2020.07.026openalex-snapshot
DNA Damage and Cancer Immunotherapy: A STING in the Tale
inferred← citeshttps://doi.org/10.1016/j.nano.2020.102169openalex-snapshot
Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition
inferred← citeshttps://doi.org/10.1016/j.path.2021.05.006openalex-snapshot
Molecular Pathology of Ovarian Epithelial Neoplasms
inferred← citeshttps://doi.org/10.1016/j.retram.2025.103494openalex-snapshot
Advances in the relationship of immune checkpoint inhibitors and DNA damage repair
inferred← citeshttps://doi.org/10.1016/j.semcancer.2018.05.004openalex-snapshot
Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.semcancer.2019.12.020openalex-snapshot
Understanding genetic determinants of resistance to immune checkpoint blockers
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.08.013openalex-snapshot
New approaches for targeting platinum-resistant ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.08.017openalex-snapshot
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.02.008openalex-snapshot
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
inferred← citeshttps://doi.org/10.1016/j.seminoncol.2026.152522openalex-snapshot
Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment
inferred← citeshttps://doi.org/10.1016/j.semradonc.2025.07.006openalex-snapshot
Emerging Systemic Therapy Considerations for Pancreatic Cancer
inferred← citeshttps://doi.org/10.1016/j.soc.2019.02.002openalex-snapshot
Immunotherapy in Ovarian Cancer
inferred← citeshttps://doi.org/10.1016/j.tibs.2018.09.004openalex-snapshot
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.tranon.2020.100994openalex-snapshot
Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.trecan.2019.06.004openalex-snapshot
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
inferred← citeshttps://doi.org/10.1016/j.trecan.2021.05.004openalex-snapshot
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises
inferred← citeshttps://doi.org/10.1016/j.trecan.2021.12.003openalex-snapshot
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.02.048openalex-snapshot
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ygyno.2016.10.023openalex-snapshot
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
inferred← citeshttps://doi.org/10.1016/j.ygyno.2016.12.021openalex-snapshot
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors
inferred← citeshttps://doi.org/10.1016/j.ygyno.2017.03.007openalex-snapshot
CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ygyno.2019.02.011openalex-snapshot
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma
inferred← citeshttps://doi.org/10.1016/j.ygyno.2019.04.014openalex-snapshot
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
inferred← citeshttps://doi.org/10.1016/j.ygyno.2019.09.008openalex-snapshot
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
inferred← citeshttps://doi.org/10.1016/j.ygyno.2019.09.021openalex-snapshot
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
inferred← citeshttps://doi.org/10.1016/j.ygyno.2020.09.045openalex-snapshot
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
inferred← citeshttps://doi.org/10.1016/j.ygyno.2021.09.011openalex-snapshot
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers
inferred← citeshttps://doi.org/10.1016/j.ygyno.2023.10.005openalex-snapshot
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
inferred← citeshttps://doi.org/10.1016/j.ygyno.2024.01.029openalex-snapshot
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival
inferred← citeshttps://doi.org/10.1016/j.ygyno.2025.02.010openalex-snapshot
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
inferred← citeshttps://doi.org/10.1016/j.ygyno.2025.04.578openalex-snapshot
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1016/s1470-2045(19)30396-1openalex-snapshot
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
inferred← citeshttps://doi.org/10.1016/s1470-2045(19)30509-1openalex-snapshot
Combining PARP inhibition with PD-1 inhibitors
inferred← citeshttps://doi.org/10.1016/s2468-1253(18)30117-1openalex-snapshot
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series
inferred← citeshttps://doi.org/10.1017/9781108582322.061openalex-snapshot
Immunotherapy for Gynaecological Cancers
inferred← citeshttps://doi.org/10.1038/bjc.2017.376openalex-snapshot
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
inferred← citeshttps://doi.org/10.1038/cgt.2016.63openalex-snapshot
Gene-expression profiling to predict responsiveness to immunotherapy
inferred← citeshttps://doi.org/10.1038/modpathol.2017.67openalex-snapshot
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
inferred← citeshttps://doi.org/10.1038/nri.2016.99openalex-snapshot
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
inferred← citeshttps://doi.org/10.1038/s41379-018-0061-3openalex-snapshot
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
inferred← citeshttps://doi.org/10.1038/s41379-021-00882-yopenalex-snapshot
Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists
inferred← citeshttps://doi.org/10.1038/s41388-019-0733-6openalex-snapshot
Base excision repair regulates PD-L1 expression in cancer cells
inferred← citeshttps://doi.org/10.1038/s41391-019-0153-2openalex-snapshot
Role of the DNA damage response in prostate cancer formation, progression and treatment
inferred← citeshttps://doi.org/10.1038/s41392-026-02954-4openalex-snapshot
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
inferred← citeshttps://doi.org/10.1038/s41416-018-0017-xopenalex-snapshot
From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
inferred← citeshttps://doi.org/10.1038/s41416-019-0674-4openalex-snapshot
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
inferred← citeshttps://doi.org/10.1038/s41416-020-01218-4openalex-snapshot
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
inferred← citeshttps://doi.org/10.1038/s41416-021-01514-7openalex-snapshot
Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer
inferred← citeshttps://doi.org/10.1038/s41416-022-01763-0openalex-snapshot
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41416-023-02311-0openalex-snapshot
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
inferred← citeshttps://doi.org/10.1038/s41416-023-02349-0openalex-snapshot
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial
inferred← citeshttps://doi.org/10.1038/s41416-024-02776-7openalex-snapshot
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
inferred← citeshttps://doi.org/10.1038/s41416-025-03032-2openalex-snapshot
Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1038/s41416-025-03179-yopenalex-snapshot
Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer
inferred← citeshttps://doi.org/10.1038/s41417-020-0174-yopenalex-snapshot
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
inferred← citeshttps://doi.org/10.1038/s41467-017-01883-9openalex-snapshot
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
inferred← citeshttps://doi.org/10.1038/s41467-018-03301-0openalex-snapshot
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41467-018-05228-yopenalex-snapshot
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
inferred← citeshttps://doi.org/10.1038/s41467-020-15315-8openalex-snapshot
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41467-022-28389-3openalex-snapshot
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41467-022-34081-3openalex-snapshot
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
inferred← citeshttps://doi.org/10.1038/s41467-025-58440-yopenalex-snapshot
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial
inferred← citeshttps://doi.org/10.1038/s41467-026-76046-wopenalex-snapshot
Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41523-021-00320-xopenalex-snapshot
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
inferred← citeshttps://doi.org/10.1038/s41568-020-0267-9openalex-snapshot
Prostate carcinogenesis: inflammatory storms
inferred← citeshttps://doi.org/10.1038/s41568-022-00503-zopenalex-snapshot
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
inferred← citeshttps://doi.org/10.1038/s41568-026-00958-4openalex-snapshot
The DNA damage response and cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41571-018-0074-3openalex-snapshot
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41571-020-00460-2openalex-snapshot
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
inferred← citeshttps://doi.org/10.1038/s41571-021-00532-xopenalex-snapshot
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
inferred← citeshttps://doi.org/10.1038/s41571-024-00937-4openalex-snapshot
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
inferred← citeshttps://doi.org/10.1038/s41598-018-25583-6openalex-snapshot
Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
showing the first 200 of 622 · page through all 622
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.